A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
about
Mesothelin-Targeted CARs: Driving T Cells to Solid TumorsAdvances in liver cancer antibody therapies: a focus on glypican-3 and mesothelinA novel high-affinity human monoclonal antibody to mesothelin.Pathogenesis of ovarian cancer: clues from selected overexpressed genes.A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity.Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapyMolecular targeted approaches for treatment of pancreatic cancer.Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.The role of mesothelin in tumor progression and targeted therapy.What is recent in pancreatic cancer immunotherapy?A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.Potential targets for pancreatic cancer immunotherapeutics.Immune therapies for malignant mesothelioma.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Amatuximab and novel agents targeting mesothelin for solid tumors.CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
P2860
Q26778759-91BFC013-5F56-46E5-A4BE-E6682C74647BQ27015134-7182A17A-4997-44F8-A37B-AB67F83B37C9Q33634221-7F17555B-66E0-45E9-944D-92ADD6484A66Q33651139-2380E55F-007E-4CA0-A3F1-013A1C2E1099Q33866381-E4B4B7FC-FC08-400B-8CD3-F5AC4AD350CFQ33959016-350ED6B0-4CA4-4C23-88F5-3853EB214102Q34335982-DB9F5A72-0285-4CAA-AB46-91F3B03E188EQ35049589-5EDC16AB-B35E-4EF7-B750-5F202062682EQ35216278-53FF7BE3-E6CF-4A32-902E-254DE1C1D2F4Q35886496-63192D71-786F-4CEF-AEFC-41B062CC18C6Q36174910-2F2C931F-2A01-4240-9143-3A4F40EC4844Q36212739-7705306E-0374-4189-B1A6-F3883C24714FQ36597831-24003DF0-2E6C-41AA-91F3-074D770B7531Q36665335-B0BA3185-56D1-449A-B36E-2F6AEDAFF5D7Q36759405-BC3C300E-AE18-422F-B4BA-62E71A8D6590Q37137924-DD1DF251-3E97-4C90-94DC-8E14253CAB3FQ37139011-75734785-AC3B-43A8-AA73-701777975ED0Q37861220-1D5C78E2-BAA4-4935-B237-5668C6B0DEACQ38212149-5F1B4D49-B883-4385-A2DD-6D8208D0A6DEQ38945853-71EEA632-CD7A-44F0-93B7-3E042274E89CQ38951943-4778AA2A-072F-49EF-B19A-09A64E8B388BQ39005715-FDFF8CBA-FD32-4725-ADB5-3EEA0501540FQ39612474-02FDB054-A252-4BE9-B55A-F2683F495C8CQ40095245-F3E48954-2B1F-48C8-8C7F-6D40E295D388Q47126660-FCB242B1-81A5-4CB9-A7B4-EE0EB7AE2733Q52590080-E1A983D5-881D-49A6-80F8-A6EAA1CCBA96Q53581193-FE21F83C-6A42-4BDB-B949-8EA9C059EA80Q55257427-95DBF423-9B52-41A1-8D0E-AEA2EB9FF0C0
P2860
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
A novel human monoclonal antib ...... nt cell-mediated cytotoxicity.
@ast
A novel human monoclonal antib ...... nt cell-mediated cytotoxicity.
@en
type
label
A novel human monoclonal antib ...... nt cell-mediated cytotoxicity.
@ast
A novel human monoclonal antib ...... nt cell-mediated cytotoxicity.
@en
prefLabel
A novel human monoclonal antib ...... nt cell-mediated cytotoxicity.
@ast
A novel human monoclonal antib ...... nt cell-mediated cytotoxicity.
@en
P2093
P2860
P1476
A novel human monoclonal antib ...... nt cell-mediated cytotoxicity.
@en
P2093
Dimiter S Dimitrov
Emily Streaker
Ira Pastan
Mitchell Ho
Xiaodong Xiao
Zhongyu Zhu
P2860
P304
P356
10.1158/1535-7163.MCT-08-0945
P577
2009-05-05T00:00:00Z